T-cell phenotypes associated with effective CAR T-cell therapy in postinduction vs relapsed multiple myeloma
نویسندگان
چکیده
منابع مشابه
STUDIES ON THE T-CELL PHENOTYPES IN CHILDREN WITH KALA-AZAR IN FARS PROVINCE, IRAN
The subpopulations of T-Iymphocytes were studied in children with visceral leishmaniasis in the active stage of disease prior to treatment (n=28) and in controls (n=15) using specific monoclonal antibodies (Behring OKT3, OKT4 and OKT8). The percentage of total peripheral blood T-Iymphocytes (CD3+ T-cells) in patients were within the same range as those of normal children (71.09± 1.07 vs68.8...
متن کاملCAR T-cell Therapy of Hematologic Malignancies: An Update in Targeted Antigens
Immunotherapy with genetically engineered T-cells that express the chimeric antigen receptor (CAR) has raised hopes for the treatment of pediatric malignancies. Although CAR T-cell development is on a fast-moving pace and evolution, the context of exploring novel targetable antigens has been neglected. In this review study, we analyze the prominent hematologic antigens targeted by engineered T-...
متن کاملNew development in CAR-T cell therapy
Chimeric antigen receptor (CAR)-engineered T cells (CAR-T cells) have yielded unprecedented efficacy in B cell malignancies, most remarkably in anti-CD19 CAR-T cells for B cell acute lymphoblastic leukemia (B-ALL) with up to a 90% complete remission rate. However, tumor antigen escape has emerged as a main challenge for the long-term disease control of this promising immunotherapy in B cell mal...
متن کاملNext frontiers in CAR T-cell therapy
Chimeric antigen receptor (CAR) T-cell therapy is entering a new era, transitioning from an experimental approach being tested in a handful of centers to a more mainstream and broadly investigated therapeutic platform with significant efforts directed towards commercial translation. CARs are synthetic receptors engineered and transduced into T cells to redirect T-cell cytotoxicity by recognitio...
متن کاملAltered T cell phenotypes associated with clinical relapse of multiple sclerosis patients receiving fingolimod therapy
Multiple sclerosis (MS) is a T cell-mediated autoimmune disease. Fingolimod, a highly effective disease-modifying drug for MS, retains CCR7+ central memory T cells in which autoaggressive T cells putatively exist, in secondary lymphoid organs, although relapse may still occur in some patients. Here, we analyzed the T cell phenotypes of fingolimod-treated, fingolimod-untreated patients, and heal...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Blood Advances
سال: 2019
ISSN: 2473-9529,2473-9537
DOI: 10.1182/bloodadvances.2019000600